A365270 Stock Overview
Curacle Co., Ltd., a bio-venture business, engages in the research and development of drugs for diseases caused by aging process and damage to blood vessels.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
curacle co.,ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩17,900.00 |
| 52 Week High | ₩21,350.00 |
| 52 Week Low | ₩8,250.00 |
| Beta | 1.87 |
| 1 Month Change | 7.38% |
| 3 Month Change | 62.14% |
| 1 Year Change | 69.83% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -41.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| A365270 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -9.2% | 2.9% | 2.7% |
| 1Y | 69.8% | 10.0% | 5.8% |
Return vs Industry: A365270 exceeded the KR Biotechs industry which returned 10% over the past year.
Return vs Market: A365270 exceeded the KR Market which returned 5.8% over the past year.
Price Volatility
| A365270 volatility | |
|---|---|
| A365270 Average Weekly Movement | 15.4% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in KR Market | 11.7% |
| 10% least volatile stocks in KR Market | 2.4% |
Stable Share Price: A365270's share price has been volatile over the past 3 months.
Volatility Over Time: A365270's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | n/a | Jaehyeon Yoo | curacle.com |
Curacle Co., Ltd., a bio-venture business, engages in the research and development of drugs for diseases caused by aging process and damage to blood vessels. Its products cover age-related vascular diseases, intractable metabolic diseases, and cancer targeting/immunotherapy. The company’s products in pipeline include CU06, which covers treatment and medical indications, such as diabetic macular edema/retinopathy, acute respiratory distress syndrome, myocardial infarction, stroke treatment, concomitantly used with immunotherapy, inflammatory bowel disease treatment, and hereditary angioedema; CU03, which is in Phase 2a clinical trial study for the treatment of age-related macular degeneration; and CU01, a diabetic nephropathy medicine that completed Phase 2a clinical trial.
curacle co.,ltd. Fundamentals Summary
| A365270 fundamental statistics | |
|---|---|
| Market cap | ₩248.01b |
| Earnings (TTM) | -₩11.59b |
| Revenue (TTM) | ₩10.29b |
24.1x
P/S Ratio-21.4x
P/E RatioIs A365270 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A365270 income statement (TTM) | |
|---|---|
| Revenue | ₩10.29b |
| Cost of Revenue | ₩16.82m |
| Gross Profit | ₩10.28b |
| Other Expenses | ₩21.86b |
| Earnings | -₩11.59b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -836.20 |
| Gross Margin | 99.84% |
| Net Profit Margin | -112.54% |
| Debt/Equity Ratio | 43.6% |
How did A365270 perform over the long term?
See historical performance and comparison